Equities Analysts Issue Forecasts for Integer Holdings Co.’s FY2024 Earnings (NYSE:ITGR)

Integer Holdings Co. (NYSE:ITGR) – Equities researchers at Zacks Research lifted their FY2024 earnings estimates for Integer in a research note issued to investors on Wednesday, May 8th. Zacks Research analyst D. Dey now expects that the medical equipment provider will post earnings of $5.26 per share for the year, up from their prior estimate of $5.25. The consensus estimate for Integer’s current full-year earnings is $5.27 per share. Zacks Research also issued estimates for Integer’s Q1 2025 earnings at $1.30 EPS, Q2 2025 earnings at $1.47 EPS, Q3 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.71 EPS, FY2025 earnings at $6.09 EPS and Q1 2026 earnings at $1.66 EPS.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. Integer had a net margin of 6.01% and a return on equity of 11.25%. The firm had revenue of $414.80 million during the quarter, compared to analysts’ expectations of $412.78 million. During the same period in the previous year, the business posted $0.87 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year.

A number of other equities research analysts have also recently issued reports on ITGR. Benchmark reissued a “buy” rating and issued a $130.00 target price on shares of Integer in a research report on Friday, April 26th. CL King assumed coverage on shares of Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 target price for the company. KeyCorp boosted their target price on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th. Finally, Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and boosted their target price for the company from $105.00 to $135.00 in a research report on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $120.50.

Integer Trading Up 0.9 %

ITGR stock opened at $114.16 on Friday. The company has a fifty day moving average price of $114.74 and a two-hundred day moving average price of $102.06. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of 39.50, a price-to-earnings-growth ratio of 1.65 and a beta of 1.12. Integer has a one year low of $69.40 and a one year high of $123.99. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.32 and a quick ratio of 2.01.

Insider Buying and Selling

In other Integer news, SVP Andrew Senn sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $113.14, for a total transaction of $565,700.00. Following the completion of the transaction, the senior vice president now owns 4,658 shares of the company’s stock, valued at $527,006.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Integer news, SVP Andrew Senn sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $113.14, for a total transaction of $565,700.00. Following the completion of the transaction, the senior vice president now owns 4,658 shares of the company’s stock, valued at $527,006.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP John A. Harris sold 312 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $113.00, for a total value of $35,256.00. Following the transaction, the executive vice president now directly owns 1,157 shares of the company’s stock, valued at approximately $130,741. The disclosure for this sale can be found here. Insiders sold 6,812 shares of company stock valued at $771,956 over the last quarter. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ITGR. Raymond James & Associates increased its stake in shares of Integer by 4.0% in the third quarter. Raymond James & Associates now owns 40,700 shares of the medical equipment provider’s stock valued at $3,192,000 after buying an additional 1,564 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Integer by 16.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,902 shares of the medical equipment provider’s stock valued at $384,000 after purchasing an additional 684 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Integer by 2.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,489 shares of the medical equipment provider’s stock valued at $1,293,000 after purchasing an additional 353 shares during the period. Park Avenue Securities LLC acquired a new stake in Integer during the 3rd quarter valued at approximately $462,000. Finally, Congress Wealth Management LLC DE increased its position in Integer by 7.7% during the 3rd quarter. Congress Wealth Management LLC DE now owns 58,605 shares of the medical equipment provider’s stock valued at $4,596,000 after purchasing an additional 4,168 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.